References

Cancer statistics, 2026

10.3322/caac.70043 · 2026 · External reference

Cancer incidence and mortality in China, 2022

10.1016/j.jncc.2024.01.006 · 2024 · External reference

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer

10.3389/fpubh.2025.1571980 · 2025 · External reference

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

10.1056/nejmoa1408440 · 2014 · External reference

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

10.1093/annonc/mdy121 · 2018 · External reference

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

10.1016/s2213-2600(22)00437-4 · 2023 · External reference

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study

10.1016/j.annonc.2026.05.692 · 2026 · External reference

ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer

10.1200/jco.18.02236 · 2019 · External reference

Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies

10.1371/journal.pone.0201425 · 2018 · External reference

A case of five-year survival after combined-modality treatment for non-small cell lung cancer with intraspinal metastasis

10.7759/cureus.20960 · 2022 · External reference

Primary intraspinal neuroendocrine tumor: A case report and literature review

10.1097/md.0000000000039196 · 2024 · External reference

Management of leptomeningeal metastases in non-small cell lung cancer

10.4103/ijc.ijc_74_19 · 2019 · External reference

Analysis of risk factors for meningeal metastasis in patients with lung adenocarcinoma following non-surgical interventions

10.3779/j.issn.1009-3419.2025.101.06 · 2025 · External reference

The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain

10.1002/cam4.3061 · 2020 · External reference

Leptomeningeal metastasis in non-small-cell lung cancer with actionable genomic alterations: Pathogenesis, diagnosis, and emerging therapeutic strategies

10.3390/cancers18132169 · 2026 · External reference

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

10.1186/s12967-022-03451-2 · 2022 · External reference

Immune-related gene expression profiling and alectinib efficacy for patients with ALK-rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study

10.1016/j.lungcan.2026.109416 · 2026 · External reference

A phase I trial of the MET/ALK/ROS1 inhibitor crizotinib combined with the VEGF inhibitor pazopanib in patients with advanced solid Malignancies

10.2147/ott.s291801 · 2021 · External reference

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers

10.1111/cas.14801 · 2021 · External reference

Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial

10.1001/jamaoncol.2018.3039 · 2018 · External reference

Update 2025: Management of non-small-cell lung cancer

10.1007/s00408-025-00801-x · 2025 · External reference

Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients

10.1111/1759-7714.13143 · 2019 · External reference

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

10.1016/j.annonc.2021.02.012 · 2021 · External reference

Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer

10.1111/cas.15777 · 2023 · External reference

International consensus on radiotherapy in metastatic non-small cell lung cancer

10.21037/tlcr-22-644 · 2022 · External reference

A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player

10.21037/tlcr-20-1145 · 2020 · External reference

Tumor primary site and histology subtypes role in radiotherapeutic management of brain metastases

10.3389/fonc.2020.00781 · 2020 · External reference